Logo
LOGIN
SIGN UP
Logo

Archive

Dive into a collection of past posts and rediscover timeless content.
BioTech Breakout: MoonLake Up 30% On FDA Wins

Feb 9, 2026

•

3 min read

BioTech Breakout: MoonLake Up 30% On FDA Wins

FDA Fast Track for Sonelokimab and an OK on HS filings have de‐risked MoonLake’s nanobody program and triggered the 30% rally. With cash into 2027 and key data readouts ahead, momentum could intensify as shorts face pressure.

Microchip Technology Says the Slump Is Ending—The Stock Is Starting to Agree

Feb 8, 2026

•

3 min read

Microchip Technology Says the Slump Is Ending—The Stock Is Starting to Agree

Q3 marks a clear turnaround as revenue, margins and cash flow recover. Analyst upgrades and renewed institutional buying point to meaningful upside if MCHP clears the key ~$80 resistance.

Which Mining Firms Are Striking It Rich in the Metals Rally?

Feb 7, 2026

•

3 min read

Which Mining Firms Are Striking It Rich in the Metals Rally?

Gold's rally has powered triple-digit gains across miners. We examine Hecla, Coeur and Kinross — winners driven by strong production, strategic M&A and robust cash returns.

Meta Platforms Posted Its Fastest Growth Guide in Years—Now What?

Feb 6, 2026

•

2 min read

Meta Platforms Posted Its Fastest Growth Guide in Years—Now What?

Meta’s 30% Q1 2026 sales guidance reignited the rally and pushed analysts to raise targets — consensus implies roughly 20–25% upside, with some forecasts as high as ~62%. The question now is whether Meta can convert heavy spending into sustained growth or if execution risk will curb the optimism.

Teradyne Inc: Sky’s the Limit for This Market, Until It Isn't

Feb 5, 2026

•

3 min read

Teradyne Inc: Sky’s the Limit for This Market, Until It Isn't

AI-fueled GPU and HBM demand — plus blowout 2026 guidance and widening margins — have pushed Teradyne to record highs. But concentrated institutional ownership and lofty expectations leave the stock vulnerable to a sharp correction.

Palantir’s Perfect 10: Blowout Earnings Spark a New Bull Case

Feb 4, 2026

•

3 min read

Palantir’s Perfect 10: Blowout Earnings Spark a New Bull Case

Record revenue, raised guidance and surging U.S. commercial demand have analysts hiking targets — and the recent pullback into support could be a buyable entry for PLTR.

CrowdStrike’s Floor Test After Fortinet’s Upgrade: What Comes Next?

Feb 3, 2026

•

3 min read

CrowdStrike’s Floor Test After Fortinet’s Upgrade: What Comes Next?

Fortinet’s upgrade gave the sector a lift and may have established a valuation floor for CrowdStrike — but AI “vibe coding” fears and high multiples mean March earnings are the real test. With shares sitting near key support, CRWD could be at a critical inflection point for investors.

2 Bitcoin ETFs to Avoid—and 1 to Watch in 2026

Feb 2, 2026

•

3 min read

2 Bitcoin ETFs to Avoid—and 1 to Watch in 2026

High fees and steep losses make ProShares' BITO and Grayscale's GBTC hard to justify. Watch BlackRock’s low‐cost iShares IBIT — big AUM, strong liquidity and a 0.25% fee.

The Time to Buy ServiceNow Is Now: Oversold and Ready for a Rebound

Feb 1, 2026

•

3 min read

The Time to Buy ServiceNow Is Now: Oversold and Ready for a Rebound

ServiceNow’s selloff has created a clear value setup—buybacks, strong cash flow and institutional buying point to upside. Generative AI momentum and an upcoming earnings catalyst could spark the rebound.

Apple Posts Record Quarter, But AI Details Remain Unclear

Jan 31, 2026

•

3 min read

Apple Posts Record Quarter, But AI Details Remain Unclear

iPhone 17-fueled demand pushed revenue to a four-year high and set new records, but Apple gave few specifics on its AI roadmap or how it will use its 2.5 billion-device base. Supply constraints and vague answers on partnerships left investors wanting clarity.

Load more

The Markets Daily

News and insights for the market’s hottest stocks.

  • Home
  • About
  • Archive
  • Privacy Policy
  • Contact Us